Everything below concerns ACTH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
== Chemistry == The substance is a cross-linked polymer of 2-fluoroacrylic acid with divinylbenzenes and 1,7-octadiene. It is used in form of its calcium salt (ratio 2:1) and with sorbitol (one molecule per two calcium ions or four fluoroacrylic acid units), a combination called patiromer sorbitex calcium.
=== Analogues === 4-AcO-DMT is closely related to psilocin (4-HO-DMT) and psilocybin (4-PO-DMT). It is a lower homologue of 4-AcO-MET, 4-AcO-DET, 4-AcO-MiPT, and 4-AcO-DiPT. Other analogues of 4-AcO-DMT include 4-AcO-DPT, 4-MeO-DMT, and 4-PrO-DMT (O-propionylpsilocin). Other related prodrugs of psilocin besides 4-AcO-DMT, 4-PrO-DMT, and psilocybin include CT-4201, EB-002, RE-109 (4-GO-DMT), and MSP-1014.
Studies have measured δ34S values of bone collagen, though the interpretation of these values was not reliable until quality criteria were published in 2009. Though bone collagen is abundant in skeletal remains, less than 1% of the tissue is made of sulfur, making it imperative that these studies carefully assess the meaning of bone collagen δ34S values.
Sources: en.wikipedia.org
=== Recurring === MC Lyte as Kai Owens, Mona's boss Obba Babatundé as Charles Thorne, Mona and Dee Dee's father; ex-husband of Phyllis and current husband of Big Dee Dee. Estelle Harris as Sophie, Mona's grandmother (and Phyllis' mother), who is white and Jewish. Corey Holcomb as Chauncey, Spencer's cousin Joey Lawrence as Brett Mahoney Coby Bell as Glen Stallworth Keith Robinson as Neil Crawford Michelle Williams as Naomi Dawson Penny Bae Bridges as Young Mona Gabby Soleil as Young Dee Dee Yvette Nicole Brown as Ceci Louis Gossett Jr. as Ray Willis, Spencer's father. Suzy Nakamura as Tina Lamman Rucker as Chase Charles Divins as Lorenzo Rowena King as Camille
== Signs and symptoms == Patients with Sack–Barabas syndrome have thin, fragile skin, especially in the chest and abdomen, that bruises easily; hands and feet may have an aged appearance. Skin is soft but not overly stretchy. Facial features are often distinctive, including protruding eyes, a thin nose and lips, sunken cheeks, and a small chin. Other signs of the disorder include hypermobility of joints, tearing of tendons and muscles, painfully swollen veins in the legs, lung collapse, and slow wound healing following injury or surgery. Infants with the condition may be born with hip dislocations and clubfeet. Unpredictable ruptures of arteries and organs are serious complications of SBS. Ruptured arteries can cause internal bleeding, stroke, or shock, the most common cause of death in patients with this disorder. Rupture of the intestine is seen in 25 to 30 percent of affected individuals, and tearing of the uterus during pregnancy affects 2 to 3 percent of affected women. Although these symptoms are rare in childhood, more than 80 percent of patients experience severe complications by the age of 40. Teenage boys are at high risk for arterial rupture, which is often fatal.
=== FDA label expansion and marketing controversy === In January 2018, the U.S. Food and Drug Administration (FDA) expanded the label for Invega Sustenna to state that the drug "may delay time to arrest and/or incarceration" in patients with schizophrenia. The revised label was based on the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study, a Janssen‑sponsored, open‑label, 15‑month trial that enrolled 444 adults aged 18 to 65 who had been taken into custody at least twice in the previous two years, and at least once in the prior 90 days; about 60% had a concurrent substance use disorder and 14% were homeless. Participants were randomized to once‑monthly paliperidone palmitate or one of seven daily oral antipsychotics. The study, conducted between May 2010 and December 2013, found a significantly longer time to treatment failure—a composite measure that included arrest and/or incarceration, psychiatric hospitalization, treatment discontinuation because of safety or tolerability, treatment supplementation because of inadequate efficacy, need for increased psychiatric services to prevent hospitalization, and suicide—in the injectable group than in the oral antipsychotic group. The label expansion, which granted Janssen three additional years of market exclusivity for paliperidone palmitate, attracted significant criticism from mental health experts and the media.
Sources: en.wikipedia.org
On its return, one of the first acts of the government was to establish new ranks for the nobility. Five hundred people from the old court nobility, former daimyo, and samurai who had provided valuable service to the Emperor were organized into a new peerage, the Kazoku, consisting of five ranks: prince, marquis, count, viscount, and baron. In the transition between the Edo period and the Meiji era, the Ee ja nai ka movement, a spontaneous outbreak of ecstatic behavior, took place. In 1885, noted public intellectual Yukichi Fukuzawa wrote the influential essay "Leaving Asia", arguing that Japan should orient itself in the image of the "civilized countries of the West", leaving behind the "hopelessly backwards", "oriental barbaric" Asian neighbors, namely Joseon Korea and Qing China. This essay certainly encouraged the economic and technological rise of Japan in the Meiji era, but it also may have laid the intellectual foundations for later Japanese colonialism in the region.
Kenyon cells synapse onto output neurons of the mushroom body, which then are thought to control stereotyped behaviors. The intracellular signaling cAMP-dependent pathways operate at Kenyon cell-to-mushroom body output neurons to depress the strength of the KC input to MBONs, thus changing the behavior evoked by the stimulus.
=== Isomers === 3-CMC is a chloromethcathinone, which has two other positional isomers, namely 2-CMC and 4-CMC. These differ in the position of the chlorine atom on the phenyl ring. As well as 3-CMC, these molecules are both known designer drugs. Since 3-CMC contains a chiral center, there are two enantiomers, namely (S)-3-CMC and (R)-3-CMC. The products are most likely on the market as a racemic mixture of the two enantiomers, since separation would result in very high costs.
== Recognition == 1989 – Award of the Mass Spectrometry Society of Japan 2002 – Nobel Prize in Chemistry 2002 – Order of Culture 2002 – Person of Cultural Merit 2002 – Honorary doctorate from Tohoku University 2003 – Honorary citizenship of Toyama Prefecture 2003 – Special Award of the Mass Spectrometry Society of Japan 2006 – Member of Japan Academy 2024 – IEEE Milestone for "LAMS-50K" (one of the 5-member development team)
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.